Pouillart P, Mathé G, Huguenin P, M'orin P, Poisson M, Buge A, Palangie T, Parrot R
Bull Cancer. 1977;64(1):125-36.
46 non resectable malignant gliomas adult patients were treated with a combination protocol of chemotherapy with administration of adriamycin, VM 26 and CCNU. The tolerance to this treatment was good except for the delayed hematological toxicity related to cumulative doses of CCNU, which limited after 5 courses of chemotherapy the possibility of further treatment with the same combination. As far as the neurological responses are concerned, 66 per 100 patients were good responders, but we found a poor relation (50%) between the degree of clinical response and regression of tumour volume in brain scan. The median survival of this group of patients was 9 months and 11 patients/46 are still alive in good state 14 months after they entered into this trial. According to these data we discuss the introduction of chemotherapy at the early stage of the disease.
46例不可切除的成年恶性胶质瘤患者接受了联合化疗方案,该方案包括给予阿霉素、威猛(VM 26)和环己亚硝脲(CCNU)。除了与CCNU累积剂量相关的延迟血液学毒性外,患者对该治疗的耐受性良好,这种毒性在5个化疗疗程后限制了使用相同联合方案进一步治疗的可能性。就神经学反应而言,每100例患者中有66例反应良好,但我们发现临床反应程度与脑部扫描中肿瘤体积缩小之间的相关性较差(50%)。该组患者的中位生存期为9个月,46例患者中有11例在进入本试验14个月后仍状况良好地存活。根据这些数据,我们讨论了在疾病早期引入化疗的问题。